AbbVie Submits FDA Biologics License Application for Etentamig
AbbVie submitted a biologics license application to the U.S. FDA for etentamig for adults with relapsed or refractory multiple myeloma. The company describes etentamig as a second-generation BCMA-directed bispecific antibody T-cell engager.